Body
WHAT:
Sexually transmitted infections, or STIs, pose a significant public health challenge. Globally, more than one million new STI cases are diagnosed each day. In a new article in The Journal of Infectious Diseases, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggest that the biomedical research community must refocus its commitment to STI research to surmount this growing global health crisis.
Scientists at Trinity College Dublin today [Monday September 9] announced a significant advance in our understanding of mild head trauma (concussive brain injury) and how it may be managed and treated in the future. It seems that repetitive impacts - as opposed to single events - cause the all-important damage to blood vessels in the brain.
Barcelona--Researchers reported today that a prospective trial comparing two screening methods for at-risk lung cancer patients found that a model used by Canadian, Australian and European public health organizations detected more cancers than the screening model used by the United States Preventive Services Task Force (USPSTF). The results were shared today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
Many patients see their tumors shrink in response to a drug, only to have them come back with a vengeance as they evolve to fend off the treatment. Oncologists want to be able to quickly detect cancer drug resistance as it emerges in their patients and identify another drug the tumors will still respond to.
Barcelona--Lung cancer screening efforts have accelerated in the last decade, with researchers showing that low dose CT screening is effective in reducing lung cancer mortality. Now, researchers in Milan report that using a blood test, accompanied by low dose CT screening, is safe and effective. The results were shared today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
Barcelona-- Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according to research reported today by Dr. M. Garassino from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
BioMILD trial demonstrates lung cancer screening using microrna blood test enhance prevention effort
Barcelona--Lung cancer screening efforts have accelerated in the last decade, with researchers showing that low dose CT screening is effective in reducing lung cancer mortality. Now, researchers in Milan report that using a blood test, accompanied by low dose CT screening, is safe and effective. The results were shared today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
Barcelona--The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized. Dr. N. Rizvi from Columbia University Medical Center in New York today presented an update from the Phase III MYSTIC study that showed poorer outcomes across treatment arms in patients with metastatic non-small cell lung cancer and mutations in STK11 or KEAP1 genes compared with those without the corresponding mutations. In patients receiving durvalumab with tremelimumab, ARID1Am was associated with survival benefits compared with ARID1Awt.
DALLAS, September 9, 2019 -The number of women with high blood pressure (HBP) when they become pregnant or who have it diagnosed during the first 20 weeks of pregnancy has spiked in the United States over the last four decades, especially among black women, according to new research in the American Heart Association's journal Hypertension.
Barcelona-- Selpercatinib was granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration in 2018 after initial data from the clinical trial LOXO-292 Investigated to Block RET-altered Tumors (LIBRETTO-001) showed the therapy demonstrated robust anti-tumor activity in a group of RET fusion-positive non small cell lung cancer patients, as well as strong evidence of durability.
Barcelona--A combination of the EarlyCDT-Lung Test followed by CT imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late stage diagnosis of lung cancer and may decrease lung cancer specific mortality, according to research presented at IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC). The research was presented by Prof. Frank Sullivan, from the University of St Andrews, St Andrews/United Kingdom.
The rate of chronic hypertension among pregnant women has increased by more than 75 percent since 1970, with black women suffering from persistent high blood pressure at more than twice the rate of white women, according to a Rutgers study.
New research from The University of Toledo College of Medicine and Life Sciences strongly suggests postural orthostatic tachycardia syndrome, or POTS, is an autoimmune disorder and may help pave the way for a simple blood test that could help physicians diagnose the condition.
Johns Hopkins Medicine researchers report they have developed and validated a tablet-based app that offers a faster, easier and more accurate way for health care providers who don't have specialized training to assess the cognitive function of people with multiple sclerosis (MS). Multiple sclerosis is a chronic neurologic illness that affects the central nervous system, resulting in a variety of symptoms including motor issues, fatigue, visual disturbance, memory and concentration concerns, and mood changes.
Women from villages in rural Indonesia are playing a key role in detecting and preventing the most common cause of death in Indonesia, cardiovascular disease, with the use of smart phones. Researchers have found that the intervention has resulted in an increase of 14.5% more appropriate use of preventive medicine than normal and a reduction in blood pressure of patients by 41%
The new health intervention, called SMARThealth, was developed by the George Institute in Australia along with researchers from The University of Manchester, and the University of Brawijaya, Indonesia.